1. 智能化融合:发展数据挖掘、集成、分析、可视化及人工智能工具,实现数据与文献、模型、计算等资源的有机融合,促进领域数智驱动科研新范式变革.
2. 标准化体系建设:以统一的数据标准管理体系为基础,系统整合全链条多源异构数据,聚焦高价值业务需求,精准构建结构合理、标注规范、语义清晰的数据资源.
3. 开放共享生态:开展数据提供方、使用方和服务方生态体系建设,实现多元主体间数据共享、共用、共治。.
4. 多模态数据处理:构建“全模态数据治理平台+高质量数据服务”一体化解决方案,提升非结构化数据处理能力.

Velpatasvir, also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in HCV replicon assays....
Reference: Reddy, Bandi Parthasaradhi; Reddy, Kura Rathnakar; Narasingam, Mogili; Krishna, Bandi Vamsi. Process for the preparation of velpatasvir. Assignee Hetero Research Foundation, India. IN 201641022433. (2018).
Valsartan is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor. Valsartan is mainly used for ...
Reference: Seki, Masahiko; Nagahama, Masaki. Synthesis of Angiotensin II Receptor Blockers by Means of a Catalytic System for C-H Activation. Journal of Organic Chemistry. Volume 76. Issue 24. Pages 10198-10206. Journal; Online Computer File. (2011)
Gadobutrol is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and in the United States. As of 2007, it was the only GBCA approved at 1.0 molar concentrations. Ga...
Wang, Chungui; Guo, Shuai; Zhang, Xuyang; Huo, Xianghong; Wang, Qi; Wang, Lichun; Wang, Jingyi. Method for preparing gadobutrol. Assignee Tianjin Kelun Pharmaceutical Research Co., Ltd., Peop. Rep. China; Sichuan Kelun Pharmaceutical Research Co., Ltd. CN 109293592. (2019).
Selinexor, also known as KPT-330, is an orally bioavailable, potent and selective XPO1/CRM1 Inhibitor. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chron...
Reference: Muthusamy, Anantha Rajmohan; Kanniah, Sundara Lakshmi; Ravi, Akash; Das, Tonmoy Chitta; Chemate, Rajendra Popat; Singh, Anil Kumar; Wagh, Yogesh Dhananjay. Novel crystalline forms of selinexor and process for their preparation. Assignee Watson Laboratories Inc., USA. WO 2018129227. (2018).
Tazemetostat (EPZ-6438) is a potent, selective, orally bioavailable inhibitor of enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the PRC2 complex. In preclinical biochemical assays, it in...
The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of TazemetostatBy: Kuntz, Kevin W.; et alJournal of Medicinal Chemistry (2016), 59(4), 1556-1564
Hexaminolevulinate hydrochloride, also known as hexyl 5-aminolevulinate HCl, is the hexyl ester of 5-aminolevulinic acid (ALA) with photodynamic properties. As a precursor of photoactive porphorins, h...
Dabrowski, Zbigniew; Kwasny, Miroslaw; Kaminski, Jaroslaw; Beldowicz, Maria; Lewicka, Lidia; Obukowicz, Bozena; Kaliszewski, Miron; Pirozynska, Ewa; Acta Poloniae Pharmaceutica; Volume 60; Issue 3; Pages 219-224; Journal; 2003
Deutivacaftor (VX-561, CTP-656) is a deuterated analog of ivacaftor developed as a CFTR potentiator with improved metabolic stability and longer half-life. In vitro, deutivacaftor enhances CFTR chlori...
Patent#: WO2019109021
Besifloxacin is a fourth-generation fluoroquinolone antibiotic. The marketed compound is besifloxacin hydrochloride. It was developed by SSP Co. Ltd., Japan, and designated SS734. SSP licensed U.S. an...
Process for the preparation of besifloxacin and pharmaceutically acceptable salts thereof Rajadhyaksha, Mangesh Narayan; Nair, Ranjeet; Shrigadi, Nilesh Balkrishna; Panandikar, Aditi Assignee Indoco Remedies Limited, India 2014 Patent Information Sep 26, 2014 IN 2013MU00023 A
Dronedarone is an antiarrhythmic, acting as a multichannel blocker. Dronedarone inhibits multiple outward potassium currents and reduces inward rapid Na current and L-type Ca channels.
Process for the preparation of dronedarone; Gutman, Arie L.; Nisnevich, Gennady; Yudovitch, Lev; Assignee ISP Investments Inc., USA 2003; Patent Information; May 15, 2003; WO 2003040120 A1
Osimertinib, also known as AZD-9291 and Mereletinib, is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have bec...
Reference: Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1. PubMed PMID: 25271963.
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
